Iovance Biotherapeutics, Inc. Q3 2025 Earnings Recap

Iovance Biotherapeutics reported a solid Q3 2025, with a 13% revenue increase driven by Amtagvi sales and improved gross margins of 43%. The company is on track to meet its full-year revenue guidance of $250 million to $300 million.

Key Takeaways

• Q3 revenue reached approximately $68 million, led by Amtagvi sales of $58 million.
• Gross margin improved significantly, from operational efficiencies and a 21% reduction in cost of sales.
• Strong real-world evidence for Amtagvi shows a 60% response rate in the second-line melanoma treatment setting, enhancing its market position.
• Iovance is advancing towards a supplemental biologics license application for non-squamous non-small cell lung cancer, with potential peak sales exceeding $1 billion in the U.S. alone.
• Cash reserves of $307 million will support operations through the second quarter of 2027 as the company focuses on achieving profitability.